Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

Core Insights - Azitra, Inc. is focused on developing innovative therapies for precision dermatology, with key programs targeting major dermatological diseases [3][5] - The company reported a net loss of $3.1 million for Q1 2025, compared to a loss of$2.9 million in Q1 2024, indicating ongoing financial challenges [7][12] - Azitra has received Fast Track designation from the FDA for its ATR-04 program, which addresses EGFRi-associated rash affecting approximately 150,000 patients annually in the U.S. [3][5] Business Highlights - The CEO highlighted the importance of 2025 for Azitra, with initial safety data for ATR-12 expected in the first half of the year and topline results by year-end [3] - The company plans to dose the first patient in the Phase 1/2 trial for ATR-04 by mid-2025, with a presentation scheduled at the prestigious ASCO 2025 conference [3][6] - Azitra's proprietary platform includes a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning for drug development [8] Financial Results - R&D expenses for Q1 2025 were $1.3 million, down from$1.5 million in Q1 2024, while G&A expenses increased to $1.9 million from$1.5 million [7][12] - As of March 31, 2025, the company had cash and cash equivalents of $3.2 million, a decrease from$4.6 million at the end of 2024 [7][12] - Total operating expenses for Q1 2025 were $3.1 million, compared to$3.0 million in the same period of 2024 [12]